Subject(s)
Adenosine Triphosphate/toxicity , Electroacupuncture/methods , Moxibustion/methods , Pain Management/methods , Pain/chemically induced , Pain/metabolism , Acid Sensing Ion Channels/metabolism , Acupuncture Therapy/methods , Animals , Male , Mice , Mice, Knockout , Purines/toxicity , Rats , Rats, Sprague-Dawley , Receptors, Purinergic P2X7/deficiency , Rodentia , TRPV Cation Channels/deficiencyABSTRACT
6-Oxo and 6-thio analogs of purine were prepared based on the initial activity screening of a small, diverse purine library against Mycobacterium tuberculosis (Mtb). Certain 6-oxo and 6-thio-substituted purine analogs described herein showed moderate to good inhibitory activity. N(9)-substitution apparently enhances the anti-mycobacterial activity in the purine series described herein. Several 2-amino and 2-chloro purine analogs were also synthesized that showed moderate inhibitory activity against Mtb.
Subject(s)
Antitubercular Agents/chemistry , Antitubercular Agents/therapeutic use , Mycobacterium tuberculosis/drug effects , Purines/chemistry , Purines/therapeutic use , Tuberculosis/drug therapy , Animals , Antitubercular Agents/pharmacology , Antitubercular Agents/toxicity , Cell Survival/drug effects , Chlorocebus aethiops , Humans , Mice , Microbial Sensitivity Tests , Purines/pharmacology , Purines/toxicity , Sulfhydryl Compounds/chemistry , Sulfhydryl Compounds/pharmacology , Sulfhydryl Compounds/therapeutic use , Sulfhydryl Compounds/toxicity , Vero CellsABSTRACT
A number of experimental models of L-DOPA-induced dyskinesia have been proposed, but these models result in a low to medium rate of dyskinetic animals with mild to severe symptoms. The objective of this study was to combine a model of 6-OHDA-induced parkinsonism and of L-DOPA-induced dyskinesia in rats to establish a reliable preclinical model. Two stereotaxic injections of 6-OHDA were administered in the left striatum. This model led to 90-100% of rats with a marked contralateral circling behaviour, significant limb use asymmetry (20%), a decrease in ipsilateral striatal dopamine content (70%) and degeneration of dopamine neurons in the substantia nigra (70%). Chronic treatment with L-DOPA was administered for 35 days and consisted of three phases with incremental daily doses. The third phase resulted in 83-90% of rats developing severe abnormal involuntary movements (AIMs) which included limb and locomotive dyskinesia, axial dystonia and orolingual dyskinesia. Reproducibility of the model, criteria of strict blinding, placebo-controlled design, randomization of study subjects and pretrial determination of sample size were used to measure efficacy of amantadine and istradefylline and to validate the protocol design. Acute or subchronic post-treatment with amantadine reduced the severity of dyskinesia while istradefylline punctually attenuated AIMs. Our experimental conditions using gradual development of dyskinesia induced by increasing doses of L-DOPA resulted in a reliable model of L-DOPA-induced dyskinesia with a high rate of dyskinetic rats.
Subject(s)
Amantadine/therapeutic use , Antiparkinson Agents/therapeutic use , Disease Models, Animal , Dyskinesia, Drug-Induced/drug therapy , Parkinsonian Disorders/drug therapy , Purines/therapeutic use , Adenosine A2 Receptor Antagonists/pharmacology , Adenosine A2 Receptor Antagonists/toxicity , Amantadine/pharmacology , Amantadine/toxicity , Animals , Antiparkinson Agents/adverse effects , Antiparkinson Agents/pharmacology , Behavior, Animal , Benserazide/pharmacology , Biological Assay , Corpus Striatum , Dopamine/physiology , Dopamine Agents/pharmacology , Dopamine Agents/toxicity , Drug Administration Schedule , Drug Evaluation, Preclinical , Enzyme Inhibitors/pharmacology , Levodopa/adverse effects , Levodopa/pharmacology , Levodopa/toxicity , Male , Oxidopamine/toxicity , Parkinsonian Disorders/chemically induced , Placebos , Purines/pharmacology , Purines/toxicity , Random Allocation , Rats , Reproducibility of Results , Rotation , Sample Size , Single-Blind Method , Sympatholytics/toxicityABSTRACT
Human ether-a-go-go-related gene (HERG) potassium channel acts as a delayed rectifier in cardiac myocytes and is an important target for both pro- and antiarrhythmic drugs. Many drugs have been pulled from the market for unintended HERG block causing arrhythmias. Conversely, recent evidence has shown that HERG plays a role in cell proliferation and is overexpressed both in multiple tumor cell lines and in primary tumor cells, which makes HERG an attractive target for cancer treatment. Therefore, a drug that can block HERG but that does not induce cardiac arrhythmias would have great therapeutic potential. Roscovitine is a cyclin-dependent kinase (CDK) inhibitor that is in phase II clinical trials as an anticancer agent. In the present study we show that R-roscovitine blocks HERG potassium current (human embryonic kidney-293 cells stably expressing HERG) at clinically relevant concentrations. The block (IC(50) = 27 microM) was rapid (tau = 20 ms) and reversible (tau = 25 ms) and increased with channel activation, which supports an open channel mechanism. Kinetic study of wild-type and inactivation mutant HERG channels supported block of activated channels by roscovitine with relatively little effect on either closed or inactivated channels. A HERG gating model reproduced all roscovitine effects. Our model of open channel block by roscovitine may offer an explanation of the lack of arrhythmias in clinical trials using roscovitine, which suggests the utility of a dual CDK/HERG channel block as an adjuvant cancer therapy.
Subject(s)
Antineoplastic Agents/pharmacology , Cyclin-Dependent Kinases/antagonists & inhibitors , Ether-A-Go-Go Potassium Channels/antagonists & inhibitors , Ion Channel Gating , Potassium Channel Blockers/pharmacology , Protein Kinase Inhibitors/pharmacology , Purines/pharmacology , Antineoplastic Agents/toxicity , Arrhythmias, Cardiac/chemically induced , Arrhythmias, Cardiac/metabolism , Cell Line , Dose-Response Relationship, Drug , ERG1 Potassium Channel , Ether-A-Go-Go Potassium Channels/genetics , Ether-A-Go-Go Potassium Channels/metabolism , Humans , Kinetics , Membrane Potentials , Models, Cardiovascular , Mutation , Potassium Channel Blockers/toxicity , Protein Kinase Inhibitors/toxicity , Purines/toxicity , Roscovitine , TransfectionABSTRACT
PURPOSE: To describe the magnetic resonance (MR) imaging findings associated with severe hypoglycemia after consumption of an illegal sexual enhancement product (Power 1 Walnut) adulterated with glibenclamide, an oral hypoglycemic agent used to treat diabetes mellitus. MATERIALS AND METHODS: Institutional review board approval was obtained for this retrospective study. Records in eight male patients with severe hypoglycemia of unknown cause, without prior treatment for diabetes, and with positive blood toxicology results for glibenclamide were reviewed. MR imaging included diffusion-weighted imaging and, in some patients, MR angiography, dynamic contrast material-enhanced perfusion MR imaging, and MR spectroscopy. RESULTS: In seven patients, there were hyperintense abnormalities on diffusion-weighted and T2-weighted images in the hippocampus and cerebral cortex, sparing the subcortical white matter and cerebellum. Three patients had abnormalities of the splenium of the corpus callosum, and one had widespread involvement, including the caudate nucleus, basal ganglia, and internal capsule bilaterally. In three patients, unilateral cortical involvement, which did not conform to the typical cerebral arterial territories, was noted. In one patient, perfusion MR imaging showed slightly increased relative cerebral blood volume, and MR spectroscopy revealed no evidence of abnormal lactate in the affected cerebral cortex. CONCLUSION: Diffusion-weighted MR imaging findings in patients with severe hypoglycemia showed typical lesions in the hippocampus and cerebral cortex, but the caudate nucleus and basal ganglia were involved in only the most severely affected patient. The splenium of the corpus callosum and internal capsule were also abnormal in three patients, and unilateral cortical lesions could be distinguished from acute ischemic stroke by the pattern of involvement and MR angiographic, perfusion, and spectroscopic findings.
Subject(s)
Brain/drug effects , Diffusion Magnetic Resonance Imaging , Drug Contamination , Glyburide/toxicity , Hypoglycemia/chemically induced , Hypoglycemic Agents/toxicity , Illicit Drugs/toxicity , Image Processing, Computer-Assisted , Magnetic Resonance Angiography , Magnetic Resonance Spectroscopy , Phytotherapy , Piperazines/toxicity , Sulfones/toxicity , Vasodilator Agents/toxicity , Adult , Aged , Blood Volume/drug effects , Brain/pathology , Cerebrovascular Disorders/chemically induced , Cerebrovascular Disorders/diagnosis , Coma/chemically induced , Coma/diagnosis , Consciousness Disorders/chemically induced , Consciousness Disorders/diagnosis , Dominance, Cerebral/physiology , Glasgow Coma Scale , Humans , Hypoglycemia/diagnosis , Lactic Acid/metabolism , Male , Middle Aged , Purines/toxicity , Retrospective Studies , Seizures/chemically induced , Seizures/diagnosis , Sildenafil CitrateABSTRACT
Two series of N9-alkylaminomethyl-, alkylpiperazino-, alkylpiperidino-substituted 1,3-dimethyl-(hexahydropyrimidino)- and (tetrahydropyrimidono)-[2,1-f]-purines were prepared and their physicochemical and pharmacological properties were described. The most active in central nervous system tests were the compounds with phenylpiperazinealkyl substituent i.e. 1,3-dimethyl-2,4-dioxo-9-[N1N4-(phenyl)-piperazinopropyl]-1, 3,6,7,8,9- hexahydropyrimidino-[2,1-f] purine 6a and its butyl and isobutyl homologs 9 and 12. The compounds depressed statistically significantly spontaneous locomotor and amphetamine activity and showed sedative, analgetic and hypothermizing properties.
Subject(s)
Behavior, Animal/drug effects , Central Nervous System Depressants/pharmacology , Purines/pharmacology , Animals , Body Temperature/drug effects , Central Nervous System Depressants/chemical synthesis , Central Nervous System Depressants/toxicity , Drug Evaluation, Preclinical , Magnetic Resonance Spectroscopy , Male , Mice , Motor Activity/drug effects , Purines/chemical synthesis , Purines/toxicity , Rats , Rats, WistarABSTRACT
Various 3-hydroxy-2-phosphonylmethoxypropyl (HPMP) and 2-phosphonylmethoxyethyl (PME) derivatives of purine [adenine (A), guanine (G), 2,6-diaminopurine (DAP), 2-monoaminopurine (MAP), hypoxanthine (HX)] and pyrimidine [cytosine (C), uracil (U), thymine (T)] have been evaluated for their antiviral properties. PMEDAP, (S)-HPMPA [and the cyclic phosphonate thereof, (S)-cHPMPA)], (S)-HPMPC, PMEG, PMEA, HPMPG and HPMPDAP proved to be effective inhibitors of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). (S)-HPMPA and (S)-cHPMPA were the most effective inhibitors of varicella-zoster virus (VZV), and (S)-HPMPC was the most effective inhibitor of cytomegalovirus (CMV). Against adenovirus (types 2, 3 and 4) and vaccinia virus again (S)-HPMPA and (S)-cHPMPA showed the greatest inhibitory activity. As a rule, the PME derivates were much less inhibitory to VZV, CMV, vaccinia and adenovirus than the HPMP derivatives. However, PMEA, PMEDAP and PMEMAP showed marked and selective activity against the human immunodeficiency virus (HIV). (S)-HPMPA was selected for further evaluation in animal model infections. It proved efficacious in the topical treatment of HSV-1 keratitis in rabbits and cutaneous HSV-1 infection in hairless mice, and in the systemic treatment of both HSV-1 and vaccinia virus infections in mice.